Alan B Lancz & Associates Inc. Lowers Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Alan B Lancz & Associates Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY) by 16.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,775 shares of the company’s stock after selling 350 shares during the quarter. Eli Lilly and Company accounts for 1.1% of Alan B Lancz & Associates Inc.’s investment portfolio, making the stock its 18th biggest holding. Alan B Lancz & Associates Inc.’s holdings in Eli Lilly and Company were worth $1,035,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LLY shares. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Citigroup lifted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Truist Financial lifted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Eli Lilly and Company stock traded down $20.94 during trading on Friday, reaching $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78. The stock’s 50 day moving average price is $761.06 and its two-hundred day moving average price is $671.38. The firm has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 13.83 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.